Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LSTA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLisata cuts upfront merger cash to $4.00/share, adds $3.00 in milestone-based CVRs
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
Merger consideration restructured: shareholders now receive $4.00 cash upfront (down from $5.00) plus contingent value rights worth up to $3.00 if two drug development milestones are met—shifting more value to uncertain future payments.
Item 1.01 verify on EDGAR → -
high
First CVR payment of $1.25/share triggers when Phase 2a glioblastoma trial completes enrollment (or expected to reach 90% enrollment), expected by December 2026—relatively near-term and achievable milestone.
Item 1.01 verify on EDGAR → -
high
Second CVR payment of $1.75/share requires filing an NDA for certepetide with FDA or foreign regulator within seven years—longer-term, higher-risk milestone dependent on successful clinical development.
Item 1.01 verify on EDGAR → -
low
Tender offer start pushed to June 1, 2026 (from May 29) and merger deadline extended to July 6 (from July 1)—short administrative delays with no stated cause for concern.
Item 1.01 verify on EDGAR → -
high
Company warns tender offer may not commence at all and closing conditions may not be satisfied—material execution risk that deal could collapse entirely.
Item 8.01 view on EDGAR →
Summary
Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash shareholders will receive from $5.00 to $4.00 per share while increasing contingent payments from $1.00 to $3.00 per share.
The new structure ties more value to two drug development milestones: a $1.25 payment when the Phase 2a glioblastoma trial completes enrollment (expected by year-end 2026), and a $1.75 payment if an NDA for certepetide is filed within seven years. This shift increases execution risk for shareholders, as the CVR payments depend on clinical and regulatory success that may never materialize.
The tender offer has been delayed by three days to June 1, 2026, and the merger deadline extended to July 6. More concerning, the company explicitly warns that the tender offer may not commence at all and closing conditions may not be satisfied, raising the possibility the deal could fall apart. Shareholders should watch for the formal tender offer filing (Schedule TO) and any further delays or amendments, which could signal trouble with financing or regulatory approvals. If you hold LSTA shares, the immediate question is whether $4.00 cash plus uncertain milestone payments is acceptable compared to holding through a standalone turnaround.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
one (1) contingent cash payment of $1.75 per CVR (the “Second Milestone Payment” and, collectively with the First Milestone Payment, the “Milestone Payments”) upon the achievement of the filing or formal acceptance for review by any Governmental Body (as defined in the Merger Agreement) of any (i) New Drug Application submitted to the FDA in the U.S. in accordance with the FDCA requesting approval to market or commercialize any pharmaceutical product that contains or incorporates the product candidate referred to as certepetide (formerly LSTA1 or CEND-1), alone or in combination with one or more other therapeutically active ingredients, including all formulations, dosages, or modes of delivery thereof (the “CVR Product”) for any indication or patient population, or (ii) analogous application or submission to any other applicable Governmental Body requesting approval to market or commercialize the CVR Product for any indication or patient population (the “Second Milestone”
The second CVR payment of $1.75 per share triggers when an NDA (or foreign equivalent) for certepetide is filed with or accepted by regulators for any indication. Payment is due 45 days after achievement, but must occur before the seventh anniversary of closing. This milestone is longer-term and higher-risk, dependent on successful clinical development.
Added in current filing · verify on EDGAR →
The CVR Agreement provides that, in the event that Parent fails to pay the First Milestone Payment in full on or prior to the date that it is due and payable, all unpaid amounts shall accrue interest commencing on such date, at a rate equal to the least of (x) ten percent (10%) per annum, (y) the Secured Overnight Financing Rate as published by the Federal Reserve Bank of New York (or any successor administrator thereof) as of such date, plus five percent (5%) per annum, and (z) the maximum rate permitted under applicable Law, in each case calculated on the basis of a 365-day year and the actual number of days elapsed, until all such amounts are paid in full.
If the acquirer fails to pay the first milestone payment on time, unpaid amounts accrue interest at the lower of 10% per year, SOFR plus 5%, or the legal maximum. This provides shareholders some protection against payment delays, though enforcement would require legal action.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
pursuant to the Amendment, the Company, Parent and Purchaser agreed that, upon commencement of the tender offer for all of the outstanding shares of common stock of the Company (the “Offer”) on June 1, 2026, the date by which Purchaser is obligated under the Merger Agreement to commence the Offer would automatically be extended from May 29, 2026 to June 1, 2026, or such other date as may be agreed to between the Company and Parent. The Amendment also extended the Outside Date (as defined in the Merger Agreement) from July 1, 2026 to July 6, 2026.
The tender offer start date was pushed from May 29 to June 1, 2026, and the outside date (deadline to close the merger) was extended from July 1 to July 6, 2026. These are short delays, likely administrative, giving parties a few extra days to complete the transaction.
Event · Item 9.01 — Financial Statements and Exhibits
Lisata Therapeutics amended its merger agreement with Kuva Labs and established contingent value rights for stockholders.
Added in current filing · verify on EDGAR →
Amendment to Agreement and Plan of Merger, dated May 29, 2026, by and among Lisata Therapeutics, Inc., Kuva Labs Inc. and Kuva Acquisition Corp.
Lisata Therapeutics has amended its merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp. The amendment modifies the terms of a previously announced acquisition transaction. The specific changes are not detailed in this 8-K, but the amendment is material enough to warrant separate disclosure and filing.
Added in current filing · verify on EDGAR →
Form of Contingent Value Rights Agreement
Lisata has established a Contingent Value Rights (CVR) Agreement, which typically provides stockholders with the right to receive additional payments if certain milestones are achieved post-merger. The filing notes that "the possibility that the milestone payments related to the CVR will never be achieved and that no milestone payments may be made," indicating these are conditional payments dependent on future events.
Added in current filing · verify on EDGAR →
The tender offer referred to in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Parent and Purchaser will file with the SEC upon commencement of the tender offer, if commenced at all.
The company clarifies that the tender offer associated with the merger has not yet started. Kuva Labs (Parent) and its acquisition subsidiary (Purchaser) have not yet filed the required Schedule TO with the SEC to commence the offer. Stockholders are advised to wait for formal tender offer materials before making any decisions.
Added in current filing · verify on EDGAR →
risks associated with the timing of the commencement of the tender, including the risk that Parent may not commence the tender offer promptly or at all; risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur
The company discloses significant execution risks around the merger. The buyer may not commence the tender offer at all, closing conditions may not be satisfied, and the transaction may not complete. These are material uncertainties that could result in the deal falling apart entirely.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify